Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose hydromorphone versus sufentanil for postoperative intravenous analgesia after orthopedic surgery
ChiCTR2400082567Phase 4Not yet recruiting
- Sponsor
- Nanjing Medical University Affiliated Nanjing Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydromorphone, sufentanil and palonosetron in postoperative pain (3 arms), sponsored by Nanjing Medical University Affiliated Nanjing Hospital. Primary endpoints: Resting Visual Analogue Score at 6 hours after surgery and Incidence of dizziness and lethargy at 48 hours after surgery. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
hydromorphonesufentanilpalonosetron
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400082567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082567.